UK High Court rules against AbbVie’s Humira patents
March 6, 2017Sales and Marketing AbbVie, Biogen, Fujifilm Kyowa Kirin Biologics, Humira, Samsung Bioepis, biosimilar
The UK High Court has ruled that two of AbbVie patents, related to dosing regimens for rheumatoid arthritis, psoriasis and …
Phase 3 data for Janssen psoriasis drug shows efficacy over Humira
March 6, 2017Research and Development, Sales and Marketing Humira, Janssen, guselkumab, psoriasis
Janssen has revealed new Phase 3 data for its human monoclonal antibody guselkumab in the treatment of adults with moderate …
Otsuka to acquire Neurovance in potential $250 million deal
March 6, 2017Sales and Marketing ADHD, Neurovance, Otsuka Pharmaceuticals
Otsuka Pharmaceuticals, a pharmaceutical firm with headquarters in Japan, has agreed to pay a potential $250 million in a deal …
Bioverativ adds new member to board of directors
March 3, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Biogen spinout, Bioverativ, have moved to consolidate its board of directors by appointing Anna Protopapas to the board. Protopapas becomes …
Gene therapy: Advanced treatments for a new era
March 3, 2017Medical Communications gene therapy
Aranca discusses the considerable advances that have occured in the last few years in gene therapy.Considerable research has been conducted …
Top Ten most popular articles on Pharmafile.com this week
March 3, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing top ten
It’s been a busy week on Pharmafile.com over the last seven days. Europe’s first biosimilar treatment for cancer continues to …
EU-US reach landmark deal on mutual recognition of manufacturing inspection
March 3, 2017Medical Communications EMA, EU, FDA, US
The European Union and the US has announced that an agreement has been made to mutually recognise inspection of drug …
Price cuts bring 14 Cancer Drugs Fund treatments into routine NHS use
March 3, 2017Medical Communications, Sales and Marketing CDF, NICE
NICE has revealed that it has reached the halfway point in its review of the old Cancer Drugs Fund (CDF) …
CMA accuses Concordia and Actavis of illegal agreement to maintain high prices
March 3, 2017Medical Communications, Sales and Marketing Actavis UK, CMA, Concordia, competition and markets authority
The Competition and Markets Authority (CMA) has alleged that Concordia and Actavis UK entered into a clandestine agreement to maintain …
Ipsen appoints new Executive Vice President
March 2, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ipsen
Ipsen has announced the appointment of Benoit Hennion as Executive Vice President and President of Primary Care. Hennion has worked …
Juno Therapeutics abandons problem leukaemia drug
March 2, 2017Juno Therapeutics has finally called time on the development of its CAR-T therapy, JCAR015, after one of the most turbulent …
Are we prepared for the ‘real world’?
March 2, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing opinion, real world data, recruitment
Dr Dilruwan Chaminda Herath, Medical Director for Chiesi Group, discusses whether the lack of impetus to push for recruitment of …
NICE approves first biliary cholangitis drug in 20 years
March 2, 2017Sales and Marketing Intercept Pharmaceuticals, intercept, liver disease, ocaliva, primary biliary cholangitis
Intercept Pharmaceuticals has announced that Ocaliva (obeticholic acid) has been approved by the National Institute for Health and Care Excellence …
Osteoporosis drugs potentially causing long-term bone weakness
March 2, 2017Research and Development osteoporosis
Medication that is used to treat those suffering from weakened bones may actually be causing further damage, new research from …
Roche’s neoadjuvant breast cancer combo therapy shows strong Phase 3 results
March 2, 2017Research and Development Herceptin, Perjeta, Roche
Roche’s combination treatment of Perjeta (pertuzumab), Herceptin (trasdtuzumab) and chemotherapy met its primary endpoint in a recent Phase 3 study. …
South Korea fines Novartis over kickbacks scandal
March 2, 2017Medical Communications, Sales and Marketing Kickback, Novartis, south korea
South Korea’s Ministry of Food and Drug Safety has fined Novartis 200 million won ($174,936) over the payment of kickbacks …
New COO for Celgene
March 1, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene
Celgene released in a statement that its Chief Operating Officer and President, Jacqualyn “Jackie” Fouse, will retire from her position. …
Pfizer plant receives FDA warning letter for contamination of medicine
March 1, 2017Manufacturing and Production Copaxone, Mylan, Pfizer, Teva, generics
The FDA has issued a warning letter to Pfizer after inspectors discovered that the plant did not protect properly against …
Graham Dunkley chooses Medica’s Pharma Cartons
March 1, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Medica Packaging
Medica Packaging is pleased to announce that Graham Dunkley, most recently of Multi Packaging Solutions (MPS) has joined Medica as …
Promising anti-cocaine treatment aims for human trials within a year
March 1, 2017Research and Development University of Cincinnati, cocaine, immunotherapy
Researchers at the University of Cincinnati (UC) have developed a monocloncal antibody designed to treat cocaine addiction; its successful showing …
